| 04/01/2026 10:25 |
Corporate Governance Report |
| 04/01/2026 08:45 |
[Delayed] Matters Concerning Controlling Shareholder, Etc. |
| 03/26/2026 17:00 |
Position and Policy Regarding Reduction of the Investment Unit |
| 03/23/2026 08:30 |
Notice Regarding Discontinuation of Development of GYM329 (Emugrobart) in Spinal Muscular Atrophy and Facioscapulohumeral Muscular Dystrophy |
| 02/25/2026 08:00 |
Other Items Provided Electronically for the Notice of Convocation of the 115th Annual General Meeting of Shareholders |
| 02/25/2026 08:00 |
Business Report of the 115th Annual General Meeting of Shareholders |
| 02/25/2026 08:00 |
Notice of Convocation of the 115th Annual General Meeting of Shareholders |
| 01/29/2026 17:00 |
Notice of Distribution of Retained Earnings |
| 01/29/2026 17:00 |
CONSOLIDATED FINANCIAL STATEMENTS (IFRS)(Non-Audited)(for the year ended December 31, 2025) |
| 01/29/2026 17:00 |
Supplementary Materials Consolidated Financial Statements for the year ended December 31, 2025 (IFRS) |
| 01/29/2026 17:00 |
Revision of the Stock Compensation System |
| 01/29/2026 15:00 |
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2025 |
| 12/30/2025 10:00 |
[Update on Disclosed Matter] Notice Concerning Completion of Making Renalys Pharma, Inc. a Wholly-Owned Subsidiary and an Absorption-Type Merger |
| 12/24/2025 08:00 |
Corporate Governance Report |
| 11/18/2025 17:30 |
Notice of Absorption-Type Merger of a Wholly-Owned Subsidiary, Renalys Pharma, Inc. |
| 10/24/2025 17:00 |
Notice Concerning Making Renalys Pharma, Inc. a Wholly-Owned Subsidiary |
| 10/24/2025 17:00 |
Supplementary Materials Consolidated Financial Statements for the nine months ended September 30, 2025 (IFRS) |
| 10/24/2025 17:00 |
CONSOLIDATED FINANCIAL STATEMENTS(IFRS)(Non-Audited)(for the nine months ended September 30, 2025) |
| 10/23/2025 14:00 |
F. Hoffmann-La Roche Announces Third Quarter Sales 2025 |
| 10/20/2025 08:30 |
Chugai and Rani Therapeutics Enter into a License Agreement for the Development and Commercialization of an Oral Formulation |
| 09/17/2025 23:30 |
Eli Lilly's Announcement Regarding Oral GLP-1 Orforglipron |
| 08/27/2025 08:00 |
Eli Lilly's Announcement Regarding Oral GLP-1 Orforglipron |
| 08/08/2025 08:00 |
Eli Lilly's Announcement Regarding Oral GLP-1 Orforglipron |
| 07/24/2025 16:00 |
Chugai to Construct a New Laboratory Building "UKX" to Strengthen Manufacturing Process Development Capabilities and Advance Environmental Initiatives |
| 07/24/2025 16:00 |
Supplementary Materials Consolidated Financial Statements for the six months ended June 30, 2025 (IFRS) |
| 07/24/2025 16:00 |
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2025) |
| 07/24/2025 14:00 |
F. Hoffmann-La Roche Announces Half Year Results 2025 |
| 04/24/2025 17:00 |
Supplementary Materials Consolidated Financial Statements for the three months ended March 31, 2025 (IFRS) |
| 04/24/2025 17:00 |
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the three months ended March 31, 2025) |
| 04/24/2025 14:00 |
F. Hoffmann-La Roche Announces First Quarter Sales 2025 |
| 04/22/2025 17:00 |
(Corrections) Notice of Partial Correction to "Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan" |
